Efficacy and Safety of Intravenous to Oral 6-Day Tedizolid Phosphate vs. Intravenous to Oral 10-Day Linezolid in Patients With Acute Bacterial Skin and Skin Structure Infection (ABSSSI)

NCT02066402 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

598

Enrollment

INDUSTRY

Sponsor class

Conditions

Bacterial Infections

Interventions

DRUG: Tedizolid (BAY119-2631)
DRUG: Placebo Tedizolid (BAY119-2631)
DRUG: Linezolid
DRUG: Placebo Linezolid

Sponsor

Bayer

Collaborators

[object Object]